Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population

Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured... Rheumatol Ther (2018) 5:355–369 https://doi.org/10.1007/s40744-018-0114-6 ORIGINAL RESEARCH Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population . . . David M. Kern Lawrence Chang Kalyani Sonawane . . . Cynthia J. Larmore Natalie N. Boytsov Ralph A. Quimbo . . . Joseph Singer John T. Hinton Sze-jung Wu Andre B. Araujo Received: February 27, 2018 / Published online: May 30, 2018 The Author(s) 2018 DMARD treatment, including conventional ABSTRACT synthetic DMARDs (csDMARD), tumor necrosis factor inhibitors (TNFi), non-TNFi, and Janus Introduction: To describe treatment patterns in kinase inhibitors (JAKi), were captured during newly diagnosed rheumatoid arthritis (RA) follow-up. patients in a large, nationally representative Results: Of the 63,101 RA patients identified, managed-care database. 73% were female; mean age was 57 years. Dur- Methods: Newly diagnosed RA patients were ing an average of 3.5 ± 2.1 years of follow-up, identified from 07/01/2006–08/31/2014. 45% of patients never received a DMARD, 52% Patients had C 1 RA diagnosis by a rheumatol- received a csDMARD (94 ± 298 mean ± SD days ogist, or C 2 non-rheumatologist RA diagnoses from index), 16% a TNFi (315 ± 448 days), 4% a C 30 days apart, or RA diagnosis followed by http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Rheumatology and Therapy Springer Journals

Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population

Download PDF
15 pages

Loading next page...
 
/lp/springer_journal/treatment-patterns-of-newly-diagnosed-rheumatoid-arthritis-patients-7SXUTedS7E
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Rheumatology; Orthopedics; General Practice / Family Medicine; Internal Medicine; Quality of Life Research
ISSN
2198-6576
eISSN
2198-6584
DOI
10.1007/s40744-018-0114-6
Publisher site
See Article on Publisher Site

Abstract

Rheumatol Ther (2018) 5:355–369 https://doi.org/10.1007/s40744-018-0114-6 ORIGINAL RESEARCH Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population . . . David M. Kern Lawrence Chang Kalyani Sonawane . . . Cynthia J. Larmore Natalie N. Boytsov Ralph A. Quimbo . . . Joseph Singer John T. Hinton Sze-jung Wu Andre B. Araujo Received: February 27, 2018 / Published online: May 30, 2018 The Author(s) 2018 DMARD treatment, including conventional ABSTRACT synthetic DMARDs (csDMARD), tumor necrosis factor inhibitors (TNFi), non-TNFi, and Janus Introduction: To describe treatment patterns in kinase inhibitors (JAKi), were captured during newly diagnosed rheumatoid arthritis (RA) follow-up. patients in a large, nationally representative Results: Of the 63,101 RA patients identified, managed-care database. 73% were female; mean age was 57 years. Dur- Methods: Newly diagnosed RA patients were ing an average of 3.5 ± 2.1 years of follow-up, identified from 07/01/2006–08/31/2014. 45% of patients never received a DMARD, 52% Patients had C 1 RA diagnosis by a rheumatol- received a csDMARD (94 ± 298 mean ± SD days ogist, or C 2 non-rheumatologist RA diagnoses from index), 16% a TNFi (315 ± 448 days), 4% a C 30 days apart, or RA diagnosis followed by

Journal

Rheumatology and Therapy – Springer Journals

Published: May 30, 2018

References

  • Epidemiology and treatment of new-onset and established rheumatoid arthritis in an insured US population
    Crane, MM; Juneja, M; Allen, J
  • Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I
    Helmick, CG; Felson, DT; Lawrence, RC
  • The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people
    Salaffi, F; Carotti, M; Gasparini, S; Intorcia, M; Grassi, W
  • The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study
    Barrett, EM; Scott, DG; Wiles, NJ; Symmons, DP
  • Trends in biologic therapies for rheumatoid arthritis: results from a survey of payers and providers
    Greenapple, R
  • Core management principles in rheumatoid arthritis to help guide managed care professionals
    Agarwal, SK
  • Burden of disease in treated rheumatoid arthritis patients: going beyond the joint
    Cutolo, M; Kitas, GD; Riel, PL
  • American College of Rheumatology guideline for the treatment of rheumatoid arthritis 2015
    Singh, JA
  • 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
    Singh, JA; Saag, KG; Bridges, SL
  • Biologic agents in rheumatoid arthritis: an update for managed care professionals
    Agarwal, SK
  • Baricitinib in patients with refractory rheumatoid arthritis
    Genovese, MC; Kremer, J; Zamani, O
  • Back to the future: oral targeted therapy for RA and other autoimmune diseases
    O’Shea, JJ; Laurence, A; McInnes, IB
  • Janus kinase inhibitors for rheumatoid arthritis
    Yamaoka, K
  • Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists
    Kamal, Khalid M.; Madhavan, S. Suresh; Hornsby, Jo Ann Allen; Miller, Lesley-Ann; Kavookjian, Jan; Scott, Virginia
  • Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients’ treatment choices
    Wolfe, F; Michaud, K
  • Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs
    Pavelka, K; Kavanaugh, AF; Rubbert-Roth, A; Ferraccioli, G
  • Societal cost of rheumatoid arthritis patients in the US
    Birnbaum, H; Pike, C; Kaufman, R; Marynchenko, M; Kidolezi, Y; Cifaldi, M
  • The direct cost of rheumatoid arthritis
    Ward, MM; Javitz, HS; Yelin, EH
  • Long-term health outcomes of patients with rheumatoid arthritis treated in managed care and fee-for-service practice settings
    Ward, MM; Lubeck, D; Leigh, JP
  • The use of administrative health care databases to identify patients with rheumatoid arthritis
    Hanly, JG; Thompson, K; Skedgel, C
  • Validation of rheumatoid arthritis diagnoses in health care utilization data
    Kim, SY; Servi, A; Polinski, JM
  • Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries
    Quan, H; Li, B; Couris, CM
  • Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis
    Khanna, R; Smith, MJ
  • Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs
    Zhang, HF; Gauthier, G; Hiscock, R; Curtis, JR
  • Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study
    Bonafede, MM; Fox, KM; Johnson, BH; Watson, C; Gandra, SR
  • Time trends in glucocorticoid use in rheumatoid arthritis: results from a population-based inception cohort 1980–1994 vs. 1995–2007
    Makol, A; Davis, JM; Crowson, CS; Therneau, TM; Gabriel, SE; Matteson, EL
  • Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans
    Schmajuk, G; Trivedi, AN; Solomon, DH
  • Trends in long-term opioid therapy for chronic non-cancer pain
    Boudreau, D; Korff, M; Rutter, CM
  • Reported side effects, bother, satisfaction, and adherence in patients taking hydrocodone for non-cancer pain
    Anastassopoulos, KP; Chow, W; Tapia, CI; Baik, R; Moskowitz, B; Kim, MS
  • Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians
    Gregorian, RS; Gasik, A; Kwong, WJ; Voeller, S; Kavanagh, S
  • Do patient-perceived pros and cons of opioids predict sustained higher-dose use?
    Thielke, SM; Turner, JA; Shortreed, SM
  • Prevention and treatment of systemic glucocorticoid side effects
    Moghadam-Kia, S; Werth, VP
  • American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
    Saag, KG; Teng, GG; Patkar, NM
  • 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
    Singh, JA; Furst, DE; Bharat, A
  • PS2-22: Accuracy of Diagnostic Codes to Identify Rheumatoid Arthritis in Archived Electronic Health System Data: Support for Future Cancer Research Network Studies of Lymphoma Risk Pathways
    Greenlee, R.; Drahos, J.; VanWormer, J.; Landgren, O.; Koshiol, J.
  • Identification of rheumatoid arthritis patients using an administrative database: a Veterans Affairs study
    Ng, B; Aslam, F; Petersen, NJ; Yu, H-J; Suarez-Almazor, ME
  • A systematic review of validated methods for identifying patients with rheumatoid arthritis using administrative or claims data
    Chung, CP; Rohan, P; Krishnaswami, S; McPheeters, ML